Nanoform Finland Oyj

NANOFH

FI4000330972

Biotechnology & Medical Research

Market Closed - Nasdaq Helsinki Other stock markets 11:29:52 2024-04-26 am EDT			5-day change	1st Jan Change
2.155 ^EUR	+6.16%		-15.16%	+35.96%

Apr. 11	Nanoform Finland to Deliver Nanomedicine Technology to Japan	MT
Apr. 11	Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan	CI

Cynthia Schwalm Resigns from Nanoform's Board of Directors

May 20, 2021 at 02:10 pm EDT

Cynthia Schwalm has resigned from Nanoform's board of directors. Cynthia will continue as a senior advisor to the CEO Edward Hæggström, with focus on US Business Development.

Latest news about Nanoform Finland Oyj

Nanoform Finland to Deliver Nanomedicine Technology to Japan	Apr. 11	MT
Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan	Apr. 11	CI
Nanoform Teams Up with PlusVitech to Repurpose Anti-Nausea Drug for Lung Cancer Treatment	Apr. 09	MT
Nanoform Finland plc and Plusvitech Partner to Repurpose Aprepitant as A Treatment for Lung Cancer	Apr. 09	CI
Nanoform Finland Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Nanoform Finland Oyj Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Transcript : Nanoform Finland Oyj, 2023 Earnings Call, Feb 29, 2024	Feb. 29
Nanoform Finland plc Receives Positive Results from its Own Pre- Clinical, In-Vivo Study of a Nanocrystalline-Enabled Apalutamide Oral Formulation	Feb. 29	CI
Transcript : Nanoform Finland Oyj - Special Call	Jan. 26
Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide	Jan. 26	CI
Nanoform Finland Starts Clinical Trial for Nanocrystalline Alternative of Prostrate Cancer Drug	Jan. 05	MT
Nanoform Finland plc Commences Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide	Jan. 05	CI
Transcript : Nanoform Finland Oyj, Q3 2023 Earnings Call, Nov 22, 2023	Nov. 22
Nanoform Finland Oyj Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 22	CI
Nanoform Finland Signs Licensing Deal for AI Technology with AstraZeneca	23-10-23	MT
Nanoform Grant Global STARMAP[®] AI License to AstraZeneca	23-10-23	CI
Transcript : Nanoform Finland Oyj, Q2 2023 Earnings Call, Aug 24, 2023	23-08-24
Nanoform Finland Oyj Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Finland’s Nanoform, Celanese to Advance Partnership in Nanoparticle-enabled Drug Delivery Study	23-06-15	MT
Nanoform and Celanese Demonstrate Enhanced Drug Delivery Through the Power of Smaller Implants	23-06-15	CI
Transcript : Nanoform Finland Oyj, Q1 2023 Earnings Call, May 25, 2023	23-05-25
Nanoform Finland Oyj Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Finnish Medicines Agency Renews Nanoform's GMP License and Nanoform Starts Clinical API Manufacturing of Blockbuster Medicine Candidate	23-05-09	CI
Nanoform Finland plc Announces Board Appointments	23-04-12	CI
Transcript : Nanoform Finland Oyj, Q4 2022 Earnings Call, Feb 28, 2023	23-02-28

Nanoform Finland Oyj is a Finland-based company that operates in the global pharmaceutical industry. The Company is an early-stage growth Company that develops various nanoforming technologies for application in the field of nanomedicine. Nanoform Finland Oyjâs business is to offer expert services in nanotechnology as well as drug particle engineering for global pharma and biotech industry. Nanoform Finland Oyj is the Parent Company of the Nanoform Group, and it has one subsidiary - Nanoform USA Inc. The Group production, research and development functions operate in Finland. The Groupâs strategy is to sell nanotechnological services widely to minimize the dependence from single customers or projects.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - Global DDF Summit

More about the company

Income Statement Evolution

More financial data

Ratings for Nanoform Finland Oyj

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.155 EUR

Average target price

4.4 EUR

Spread / Average Target

+104.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NANOFORM FINLAND OYJ	+35.96%	171M
IQVIA HOLDINGS INC.	+1.51%	42.59B
MODERNA, INC.	+8.57%	40.65B
LONZA GROUP AG	+49.22%	40.57B
CELLTRION, INC.	-12.36%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.92%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.17B
MEDPACE HOLDINGS, INC.	+29.17%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.7B
UNITED THERAPEUTICS CORPORATION	+6.35%	11.1B

Other Biotechnology & Medical Research

Nanoform Finland Oyj

Equities

NANOFH

FI4000330972

Biotechnology & Medical Research

Cynthia Schwalm Resigns from Nanoform's Board of Directors

Latest news about Nanoform Finland Oyj

Chart Nanoform Finland Oyj

Company Profile

Income Statement Evolution

Ratings for Nanoform Finland Oyj

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research